Introduction
============

Statins are generally well tolerated drugs. Severe adverse events are rare, but hepatotoxicity, myopathy, and rhabdomyolysis are well known. One to 5% of patients develop muscle pain symptoms often leading to discontinuation of treatment (Thompson et al., [@B55]). A comprehensive explanation for the development of the described adverse events has not yet been found. One plausible mechanism proposes inhibition of an early step of the cholesterol biosynthesis, reducing not only cholesterol as intended, but also production of mevalonate pathway products like ubiquinone (Coenzyme Q10) or isoprenoids/terpenoids (Baer and Wortmann, [@B4]; Marcoff and Thompson, [@B38]). On the other hand it was shown that highly metabolized statins like atorvastatin were associated with the highest risk for adverse events (Law and Rudnicka, [@B33]; Silva et al., [@B50]). This is further emphasized by reports of increased numbers of adverse events when statins are co-administered with known inhibitors of statin metabolizing enzymes. A striking example is the fibrate gemfibrozil where combinations with cerivastatin have greatly increased the rate of rhabdomyolysis (Neuvonen et al., [@B40]) due to the inhibitory effect of gemfibrozil and its glucuronide metabolite on CYP2C8 and OATP1B1 dependent metabolism and transport, respectively (Shitara and Sugiyama, [@B49]). After the death of several people caused by this co-medication, it was decided to withdraw cerivastatin from the market.

Recent observations highlight the role of certain metabolites for adverse events or response to atorvastatin. Hermann et al. ([@B28]) compared the pharmacokinetics of atorvastatin and its metabolites in healthy controls and myopathy patients. Interestingly, myopathy patients had 2.4- and 3.1-fold increased AUC values for atorvastatin-lactone and para-hydroxy-atorvastatin, respectively. Moreover, by assessing the myotoxic potency of atorvastatin and metabolites in primary skeletal muscle cells, it was found that atorvastatin-lactone had a 14-fold higher potency to induce cell-death compared to atorvastatin-acid (Skottheim et al., [@B51]). These facts point to an involvement of certain metabolites in the development of statin-associated adverse events. Furthermore, atorvastatin is administered as active acid form but like other statins it is also found with nearly equal AUC in its inactive lactone form (Kantola et al., [@B30]). Both, the acid and the lactone form are substrates of CYP3A4 and CYP3A5, which convert them to the respective para- (pOH) and ortho- (oOH) hydroxy-metabolites. However, due to their higher lipophilicity the lactones are much better substrates with identical (oOH) or even six-fold higher (pOH) *V*~max~ and about 20-fold lower *K*~m~, due to better access to the hydrophobic substrate channel of the CYP enzyme near the membrane surface (Jacobsen et al., [@B29]). It has therefore been suggested that elimination of atorvastatin may proceed primarily via hydroxylation of atorvastatin-lactone and not via hydroxylation of the parent compound (Jacobsen et al., [@B29]).

We therefore hypothesized that enzymatic conversion between atorvastatin-acid and atorvastatin-lactone and vice versa may constitute an additional level of variation that could in principle be affected by both genetic and non-genetic factors. Conversion of atorvastatin to the lactone has been reported to occur spontaneously at low intestinal pH (Kearney et al., [@B31]) but proceeds predominantly enzymatically at physiological pH (Goosen et al., [@B23]). Enzymatic formation was shown to occur via acyl-glucuronidation followed by spontaneous conversion to the lactone (Prueksaritanont et al., [@B43]). Recently we could show that UDP-glucuronosyltransferase UGT1A3 is the main enzyme responsible for the lactonization of atorvastatin. As a result, *UGT1A*-polymorphisms affecting UGT1A3 expression were found to significantly increase atorvastatin-lactone formation (Riedmaier et al., [@B45]).

The reverse reaction, hydrolysis of the lactone to the open acid conformation may happen chemically or enzymatically via esterases or paraoxonases (Testa and Mayer, [@B53]). Such a conversion by paraoxonase 1 (PON1) has been shown for simvastatin and lovastatin (Billecke et al., [@B7]) and by paraoxonase 3 (PON3) for lovastatin (Draganov et al., [@B17]). Hydrolysis of atorvastatin-lactone by these enzymes has not been examined before to the best of our knowledge. The three members of the paraoxonase family, PON1, PON2, and PON3, are primarily lactone hydrolyzing enzymes and share an amino acid identity of ∼65%. The PON1 structure consists of a six-bladed beta-propeller containing two Ca^2+^ ions necessary for enzyme stability and activity (Draganov, [@B15]). The activity of PON3 was also found to be Ca^2+^ dependent (Lu et al., [@B36]). Polymorphisms of *PON1* have been studied extensively in the context of its antioxidative potential in coronary artery disease and stroke (Ranade et al., [@B44]; Banerjee, [@B5]; Dahabreh et al., [@B13]) and most recently an involvement in the generation of the active metabolite of clopidogrel has been proposed (Bouman et al., [@B8]). Several of the studied polymorphisms indeed affect PON1 expression or activity. A functional promoter polymorphism (−*108T* \> *C*; rs705379) with variant allele frequency (VAF) of 38.9% in Caucasians was reported to disrupt the binding site for transcription factor Sp1 (Deakin et al., [@B14]) or AhR (Gouédard et al., [@B24]). Two coding polymorphisms (Q192R; rs662; VAF = 35.8% in Caucasians; L55M; rs854560; VAF = 39.7% in Caucasians) were shown to change the catalytic activity for several substrates (Costa and Furlong, [@B12]). Much less is known about the variability of PON3 and potential polymorphic markers for expression and function. Although several promoter polymorphisms were studied in relation to PON1 substrates their functional relevance remained unclear (Marsillach et al., [@B39]).

In this study, we hypothesized that paraoxonases may play an active role in the hydrolysis of atorvastatin-lactone, and that inter-patient variation in the expression and activity of these enzymes could be a determinant of atorvastatin response and/or toxicity. We investigated this hypothesis *in vitro* in a large human liver bank. By determining the population variability and using correlation analysis we provide evidence that both PON1 and PON3 contribute to atorvastatin-lactone hydrolysis. Further, we investigated the influence of 40 genetic polymorphisms at the *PON*-locus as well as of several non-genetic factors on expression and function of these genes. We identified several polymorphisms and haplotypes that are associated with changes in atorvastatin δ-lactone hydrolysis and PON expression. Hence, this comprehensive analysis renders the *PON*-locus a promising candidate that could influence patients' response to atorvastatin treatment.

Results
=======

General role of enzymatic lactone hydrolysis
--------------------------------------------

First experiments based on published results for lovastatin hydrolysis indicated that in human liver microsomes both spontaneous and enzymatic conversion of lovastatin-lactone and atorvastatin-lactone to the acid forms occurs. Enzymatic compared to spontaneous hydrolysis, the latter of which was assessed by identical incubation with heat-inactivated protein fractions, was found to be 1.3-fold higher for lovastatin-lactone and 3.8-fold higher for atorvastatin-lactone in a pooled microsomal fraction (data not shown). In all subsequent analyses with atorvastatin-lactone, control incubations with heat-inactivated protein (95°C, 5 min) were included and the respective background was subtracted.

Variability of microsomal atorvastatin-lactone hydrolysis
---------------------------------------------------------

Next we determined enzymatic atorvastatin-lactone hydrolysis in a large number of microsome samples (*N* = 142). Establishing the atorvastatin-lactone hydrolysis assay, we could show that the activity was increased by approximately 20% by adding 1 mM CaCl~2~, although these reactions are not depending on co-substrates. Figure [1](#F1){ref-type="fig"} shows the variability of atorvastatin-lactone hydrolysis in our cohort of human liver samples. The fraction of enzymatic lactone hydrolysis ranged from 0 to 42% of total atorvastatin-acid formation indicating a large interindividual variability of the enzymatic fraction of the reaction. Comparison of the coefficients of variation revealed similar variability for UGT1A3-dependant lactone formation (Riedmaier et al., [@B45]) and enzymatic lactone hydrolysis (62 and 54%, respectively). Of note, UGT enzymes are only active in the presence of UDP-glucuronic acid. This cofactor was not included in the atorvastatin-lactone hydrolyzing assay.

![**Frequency histogram (left axis) and cumulative frequency (right axis) showing population distribution of the hydrolysis of atorvastatin-lactone (10 μM) to atorvastatin-acid in human liver microsomes (*N* = 142)**. Incubations (5 μg of microsomal protein) were performed in the presence of 1 mM CaCl at 37°C for 30 min. Atorvastatin-acid was quantitated by LC--MS/MS analysis.](fphar-02-00041-g001){#F1}

Candidate esterase screening
----------------------------

Our next aim was to identify the enzyme(s) responsible for this conversion. Since several enzymes known to possess esterase activity were possibly involved (Testa and Mayer, [@B53]), we used mRNA profiling data previously obtained by microarray analysis of the liver samples (Schröder et al., manuscript submitted). Table [1](#T1){ref-type="table"} shows the results of a correlation analysis between mRNA expression data of a selection of candidate esterases and enzymatic atorvastatin-lactone hydrolysis activity in the human livers. The analysis included acetylcholinesterase (ACHE), acyl-CoA thioesterase 1 (ACOT1), albumin (ALB), butyrylcholinesterase (BCHE), carboxyl ester lipase (CEL), carboxylesterase (CES1, 2, 3, 4, 7), paraoxonases (PON1, 2, 3), lysosomal acid, cholesterol esterase (LIPA), and sialic acid acetylesterase (SIAE). Interestingly, this analysis identified PON1 and PON3, already known to be involved in the hydrolysis of simvastatin and lovastatin (Draganov et al., [@B17]; Suchocka et al., [@B52]) as the two top candidates. Significant correlations (Holm-adjusted *P* \< 0.05) were also observed for BCHE, CES3 (positive) and PON2, LIPA (negative).

###### 

**Correlation analysis of candidate gene expression and atorvastatin-lactone hydrolysis**.

                                ACHE              ACOT1   ALB    BCHE                  CEL    CES1              CES2   CES3
  ----------------------------- ----------------- ------- ------ --------------------- ------ ----------------- ------ ---------------------
  Atorvastatin-acid formation   *r*~s~ = 0.21\*   n.s.    n.s.   *r*~s~ = 0.38\*\*\*   n.s.   *r*~s~ = 0.24\*   n.s.   *r*~s~ = 0.35\*\*\*

                                CES4   CES7   PON1                  PON2                   PON3                  LIPA                   SIAE                 
  ----------------------------- ------ ------ --------------------- ---------------------- --------------------- ---------------------- -------------------- --
  Atorvastatin-acid formation   n.s.   n.s.   *r*~s~ = 0.40\*\*\*   *r*~s~ = −0.39\*\*\*   *r*~s~ = 0.52\*\*\*   *r*~s~ = −0.32\*\*\*   *r*~s~ = −0.27\*\*   

*\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001*.

Population variability of microsomal PON1 and PON3 expression
-------------------------------------------------------------

In further experiments we concentrated on PON1 and PON3, because their expression showed the strongest correlation to atorvastatin-lactone hydrolysis. To quantitate mRNA transcripts by real-time PCR, we first carried out RT-PCR experiments to quantitate distinct transcripts described for PON1 (four splice-variants; Ensembl: ENSG00000105852) and PON3 (nine splice-variants; Ensembl: ENSG00000005421). We identified the predicted PON1 and PON3 *wild type* transcripts and a novel variant PON3 mRNA species, which was shown by sequence analysis to contain an additional exon of 144 bp (corresponding to 48 amino acids) between exons 3 and 4. No other PON3 variants were detected using primers for full-length mRNA amplification in a subset of 20 samples. On average, this splice-variant was 3.1-fold less expressed compared to *wild type*. When comparing the coefficients of variation, mRNA levels of PON3 *wild type* and *variant* were similarly variable (40 and 43%, respectively). Quantification of mRNA expression of PON1 and PON3 by self-designed specific TaqMan assays revealed that PON3 wild type mRNA was on average 5.1-fold higher expressed than PON1 mRNA (for correlations see below). PON1 mRNA had a high coefficient of variation (150%).

Protein expression of PON1 and PON3 was quantified by Western blot analysis using monoclonal primary antibodies. PON1 was identified as a triple band in a range of approximately 35--40 kDa, in agreement with earlier data on purified human serum paraoxonase (Furlong et al., [@B19]; Gan et al., [@B20]; Figure [2](#F2){ref-type="fig"}A). These bands occurred only in human liver microsomes but not in cytosol. PON3, on the other hand, was found as a single band at 38 kDa in human liver microsomes. In cytosolic samples of the same livers as well as in a sample prepared from primary human hepatocytes, two bands at 21 and 35 kDa were identified, whereas the 38-kDa band was absent (Figure [2](#F2){ref-type="fig"}B). The PON3 *variant* was not detected. Endoglycosidase treatment was performed to test whether glycosylation was responsible for the various immunoreactive proteins. Treatment of human liver microsomes lead to a shift of the detected bands toward a single 35 kDa band with both antibodies (Figure [2](#F2){ref-type="fig"}C). This finding suggested that PON1 and PON3 are highly glycosylated proteins in microsomes. Remarkably, the 35 kDa band, presumably representing the unglycosylated PON1 and PON3 forms corresponded to one of the two PON3 bands detected in human liver cytosol and in hepatocytes. The observed microsomal pattern of three bands for PON1 and one band for PON3 corresponded to three reported glycosylation sites (amino acids N226, N252, and N323) on PON1 and one site (N323) on PON3 (Liu et al., [@B35]). For quantification, the liver samples were analyzed in their glycosylated state and the relevant signals were combined.

![**Immunoblots of human liver cytosol (HLCs) and microsomes (HLMs) of livers 1--5 stained with specific antibodies against **(A)** PON1 and **(B)** PON3 (performed on identical blot after stripping)**. Analysis was performed on cytosolic and microsomal fractions of livers 1--5, on a human liver microsome pool (lane 11) and on lysate of primary human hepatocytes. **(C)** Deglycosylation was performed by analysis with (+) or without (−) pretreatment by endoglycosidase PNGase F.](fphar-02-00041-g002){#F2}

Taken together, these analyses revealed that both PON1 and PON3 varied considerably with regard to the analyzed phenotypes of expression and atorvastatin-lactone hydrolysis. Table [2](#T2){ref-type="table"} presents an overview of the PON population variability parameters at mRNA and protein/function levels. All measured phenotypes were not normally distributed in our Caucasian liver donor cohort. The coefficient of variation was lowest for PON3 mRNA and activity, higher for PON1 and PON3 protein expression and highest for PON1 mRNA expression.

###### 

**Population variability of hepatic PON1 and PON3 expression phenotypes**.

                                 PON1     PON3                            
  ------------------------------ -------- ------- ------- ------- ------- --------
  Minimum                        0.61     51.40   7.29    2.20    0.90    6.67
  Median                         5.84     620.0   28.73   9.50    14.10   309.70
  Maximum                        120.30   2200    73.74   22.51   74.65   816.0
  Ratio max./min.                196.25   42.80   10.12   10.23   82.94   122.34
  Normal distribution            No       No      No      No      No      No
  Sample skewness                6.88     1.05    0.67    0.58    1.44    0.30
  Coefficient of variation (%)   150      69      40      43      74      54

Identification of responsible hydrolyzing enzymes by correlation analysis
-------------------------------------------------------------------------

To further substantiate the involvement of PON1 and PON3 in atorvastatin-lactone hydrolysis, correlation analysis was performed. As shown in Table [3](#T3){ref-type="table"}, rather strong associations above *r*~s~ \> 0.5 (i.e., $r_{5}^{2}$ \> 0.25; highlighted cells) were obtained for three parameter-pairs. Most notably, atorvastatin-lactone hydrolysis was correlated with similarly high Spearman coefficients to both, PON1 and PON3 protein expression, indicating that both enzymes contribute approximately equally to the microsomal enzymatic reaction. Furthermore the mRNAs of PON1 and PON3 (*wildtype* and *splice-variant*) were also significantly correlated to activity, although with lower Spearman coefficients. Moreover, correlations were also observed between transcripts, as well as between PON1 and PON3 protein indicating co-regulation of these two paraoxonases.

###### 

**Correlation analyses of PON1 and PON3 expression and microsomal atorvastatin-lactone hydrolysis**.

  PON1 protein          PON3 WT mRNA (exon 3--4)   PON3 VAR mRNA (exon 3a--4)   PON3 protein          Atorvastatin-acid formation   
  --------------------- -------------------------- ---------------------------- --------------------- ----------------------------- --------------------------------
  *r*~s~ = 0.45\*\*\*   *r*~s~ = 0.42\*\*\*        *r*~s~ = 0.40\*\*\*          n.s.                  *r*~s~ = 0.28\*\*\*           **PON1 mRNA (exon 8--9)**
                        *r*~s~ = 0.27\*\*\*        *r*~s~ = 0.28\*\*\*          *r*~s~ = 0.48\*\*\*   ***r*~s~ = 0.60\*\*\***       **PON1 protein**
                                                   ***r*~s~ = 0.90\*\*\***      *r*~s~ = 0.31\*\*\*   *r*~s~ = 0.33\*\*\*           **PON3 WT mRNA (exon 3--4)**
                                                                                *r*~s~ = 0.32\*\*\*   *r*~s~ = 0.32\*\*\*           **PON3 VAR mRNA (exon 3a--4)**
                                                                                                      ***r*~s~ = 0.62\*\*\***       **PON3 protein**

*\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001*.

Genetic variability at the PON-locus
------------------------------------

We analyzed the genetic variability at the *PON-*locus to select known functional SNPs that cover the coding and regulatory regions of the two candidate genes PON1 and PON3. In addition, we included tagging SNPs selected for the less well characterized *PON3* gene. In total we genotyped 7 promoter SNPs, 11 coding SNPs, 14 intronic SNPs, and 1 *3*′*UTR* polymorphism of *PON3* including the selected tagging SNPs. Furthermore three promoter SNPs, two amino acid changing polymorphisms of *PON1*, and two intergenic polymorphisms located between the two genes were included. A summary of the selected polymorphisms including a comparison of the measured VAF with published data is shown in Table [A1](#TA1){ref-type="table"} in Appendix. Major frequency deviations were observed for some polymorphisms derived from the Seattle SNP database, probably because only 23 subjects had been included in their analyses. For SNP 19, only data from a Chinese cohort was available and this polymorphism was much more common in our Caucasian population.

Calculation of pairwise LD values at the *PON*-locus revealed a block of tightly linked polymorphisms comprising the *PON3* promoter region, several intronic polymorphisms and the synonymous polymorphisms *F21F* (rs13226149), and *A99A* (rs1053275; *D*′ = 0.88--1.0; *r*^2^ = 0.04--1.0; Figure [3](#F3){ref-type="fig"}). Of note, this block is also linked to the −*1741G* \> *A PON1* promoter polymorphism (*D*′ = 0.49--1.0; *r*^2^ = 0.09--0.43). Linkage was also detected between *PON1* promoter polymorphisms and L55M (*D*′ = 0.59--0.87; *r*^2^ = 0.14--0.19). *PON1* Q192R on the other hand was only linked to L55M (*D*′ = 0.95; *r*^2^ = 0.23), but neither to *PON1* promoter polymorphisms nor to polymorphisms of the *PON3* linkage block. Linkage was additionally detected between the rare polymorphisms *PON3*--*794C* \> *T*, *3*′*UTR* rs17885558 and the intergenic polymorphism rs7778771 (VAF = 1.3%; *D*′ = 1; *r*^2^ = 1).

![**Pairwise linkage disequilibrium is shown for the 40 polymorphisms genotyped in this study**. The map was generated using Haploview 4.2. Numbers represent *D*′ values. *D*′ = 1: bright red (LOD \> 2) or blue (LOD \< 2); *D*′ \< 1: shades of pink (LOD \> 2) or white (LOD \< 2).](fphar-02-00041-g003){#F3}

### Association of PON polymorphisms with PON-related phenotypes

Univariate analysis was carried out for association between single SNP genotypes and the PON phenotypes, atorvastatin-lactone hydrolysis, PON1 and PON3 protein expression (Figures [4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"}).

![**Boxplots of PON1 and PON3 protein expression and microsomal atorvastatin-lactone hydrolysis in liver microsomes for indicated polymorphisms**. Heterozygotes and homozygotes of variant allele are compared with homozygotes of reference allele by Wilcoxon--Mann-- Whitney-tests significance levels are indicated for *P* \< 0.05 (\*), *P* \< 0.01 (\*\*), and *P* \< 0.001 (\*\*\*).](fphar-02-00041-g004){#F4}

The three linked PON1 promoter polymorphisms −108T \> C, −832G \> A, and −1741G \> A were associated with significantly increased atorvastatin-lactone hydrolysis (up to 1.1-fold increased median values in heterozygous or 1.6- to 1.7-fold in homozygous carriers, respectively). These changes corresponded to increased PON1 protein (1.5- to 1.7-fold higher in heterozygous and 2.3- to 3.0-fold in homozygous samples, respectively; tested by Wilcoxon--Mann--Whitney, not adjusted for multiple testing) whereas PON3 protein was unchanged in these variants. Similar changes were seen for the corresponding mRNA transcripts (data not shown). Two amino acid changes in PON1, L55M, and Q192R, previously described to affect the kinetics of various substrates (Costa and Furlong, [@B12]) were not consistently associated with changes in either atorvastatin-lactone hydrolysis or PON1/PON3 protein expression, although there was a trend for decreased PON1 expression in relation to L55M and a trend for increased PON1 expression in relation to Q192R (Figure [5](#F5){ref-type="fig"}).

![**Boxplots of PON1 and PON3 protein expression and microsomal atorvastatin-lactone hydrolysis in liver microsomes for indicated polymorphisms**. Heterozygotes and homozygotes of variant allele are compared with homozygotes of reference allele by Wilcoxon--Mann-- Whitney-tests significance levels are indicated for *P* \< 0.05 (\*), *P* \< 0.01 (\*\*), and *P* \< 0.001 (\*\*\*).](fphar-02-00041-g005){#F5}

Linkage analysis of *PON3* SNPs revealed *F21F* (rs13226149) as a suitable marker SNP for a haplotype block comprising several *PON3* promoter polymorphisms, *A99A* (rs1053275), and several intronic variations (Figure [3](#F3){ref-type="fig"}). *F21F* was associated with increased atorvastatin-lactone hydrolysis and with increased PON1 protein expression, but not with PON3 expression (Figure [6](#F6){ref-type="fig"}).

![**Boxplots of PON1 and PON3 protein expression and microsomal atorvastatin-lactone hydrolysis in liver microsomes for indicated polymorphisms**. Heterozygotes and homozygotes of variant allele are compared with homozygotes of reference allele by Wilcoxon--Mann-- Whitney-tests significance levels are indicated for *P* \< 0.05 (\*), *P* \< 0.01 (\*\*), and *P* \< 0.001 (\*\*\*).](fphar-02-00041-g006){#F6}

In contrast to the SNPs above, which were only associated with PON1 expression, the intergenic variation at +*12285* (var55146), was associated with 1.8-fold increased PON3 protein but only minimally changed activity or PON1 protein. Because only one homozygote was found for this variant, homozygous and heterozygous carriers were analyzed together (Figure [6](#F6){ref-type="fig"}).

### Analysis of PON-haplotypes and their association with PON-related phenotypes

Based on the SNP genotyping data haplotypes for the *PON*-locus were deduced. To limit the number of generated haplotypes we only included SNPs with VAF \< 2% (see [Materials and Methods](#s1){ref-type="sec"}). Furthermore, because the above analysis revealed that PON3 polymorphisms are associated with changes in PON1 phenotype we defined the haplotypes such that they included both genes and the intergenic region. This lead to the definition of 13 haplotypes with predicted frequencies between 0.022 and 0.206 (Table [4](#T4){ref-type="table"}). In order to classify functionally relevant haplotypes, we included the results from the univariate analyses to derive seven major haplotypes. Thus, haplotypes *^\*^3* to *^\*^7* comprised the *PON3* linkage block including F21F and/or *PON1* promoter SNPs (Figure [3](#F3){ref-type="fig"}). Haplotype *^\*^2* was defined by the intergenic variant +12285, and *^\*^1* comprised all haplotypes lacking these variants. Of note, definition of these haplotypes did not consider the amino acid variants L55M and Q192R, which had no functional influence in this study.

###### 

**Structure of deduced *PON*-haplotypes**.

![](fphar-02-00041-t001)

Association of these seven haplotypes revealed that atorvastatin-lactone hydrolysis was markedly increased in carriers of haplotypes *^\*^2* (1.7-fold) and *^\*^6* (1.6-fold) as compared to homozygotes of haplotype *^\*^1* (Figure [7](#F7){ref-type="fig"}). Less pronounced but still significant changes were also found between carriers of haplotypes *^\*^2, ^\*^3, ^\*^4*, and *^\*^6* as compared to heterozygous carriers of *^\*^1*. PON1 mRNA expression was increased approximately two-fold in *^\*^3*, *^\*^4*, *^\*^*5, *^\*^7* and 2.7-fold in the *^\*^6* haplotype carriers but only marginally in the *^\*^2* haplotype. PON1 protein expression resembled the mRNA pattern with ∼2.1- and 1.6-fold increased expression in *^\*^2* and *^\*^7*, respectively, ∼2-fold increase in *^\*^3*, *^\*^4*,*^\*^5*, and 3.3-fold increase in *^\*^6*. For PON3 no significant associations were found with respect to these haplotypes, although we noted increased expression of PON3 protein in most carriers of the ^\*^2 haplotype, which includes the above mentioned var55146.

![***PON*-locus haplotype--phenotype relationships in human liver**. Atorvastatin-lactone hydrolysis, PON1 and PON3 mRNA and microsomal protein are displayed for the indicated haplotypes. Horizontal lines indicate the median. Wilcoxon--Mann--Whitney-tests were applied to compare *\*2* to *\*7* carriers with *\*1*/*\*1* (marked by \*) or *\*1* carriers (marked by \#). Significance levels not adjusted for multiple testing are indicated for *P* \< 0.05 (\* or \#), *P* \< 0.01 (\*\* or \#\#), and *P* \< 0.001 (\*\*\* or \#\#\#). After adjusting for multiple testing *\*3*, *\*4*,*\*5*,*\*7* against *\*1*/*\*1* or *\*3* and*\*4* against *\*1* were significantly different on PON1 mRNA level and *\*2* to *\*7* against *\*1*/*\*1* or *\*3*, *\*4*, and *\*6* against *\*1* were significantly different on PON1 protein level.](fphar-02-00041-g007){#F7}

Influence of non-genetic factors and multivariate analysis
----------------------------------------------------------

Univariate analysis revealed that in patients with hepatocellular carcinoma (HCC) compared to patients with metastases PON1 protein expression was decreased 1.3-fold (*P* \< 0.05), whereas in patients with cholangiocellular carcinoma (CCC) compared to patients with metastases, PON3 expression was 1.7-fold decreased (*P* \< 0.05). Interestingly, clinically elevated C-reactive protein (CRP) levels (\> 8.2 mg/l) were associated with 2.3-fold lower PON1 (*P* \< 0.01), 2.6-fold lower PON3 (*P* \< 0.01), and 1.7-fold lower atorvastatin-lactone hydrolysis (*P* \< 0.05). Similarly, elevated levels of γ-glutamyl transferase (GGT; \>64 in men/\>36 in women) were associated with 1.4-fold decreased PON1 and PON3 expression as well as atorvastatin-lactone hydrolysis (*P* \< 0.01). Bilirubin levels higher than 1.2 mg/dl were associated with 1.8-fold decreased PON3 expression (*P* \< 0.01) and 1.3-fold decreased atorvastatin-lactone hydrolysis (*P* \< 0.05). Significant differences between non-cholestasic and cholestatic patients (Nies et al., [@B42]) were identified for PON3 expression (decreased 1.6-fold, *P* \< 0.01) and atorvastatin-lactone hydrolysis (decreased 1.4-fold, *P* \< 0.05). Presurgical drug exposure to omeprazole or pantoprazole was associated with a significant decrease of PON3 mRNA (1.3-fold, *P* \< 0.05), protein (1.6-fold, *P* \< 0.01), and activity (1.7-fold, *P* \< 0.01) compared to patients receiving no drugs.

Multivariate linear models and step-wise model selection were applied to determine the contribution of polymorphisms and non-genetic factors to atorvastatin-lactone hydrolysis and PON1 and PON3 expression variability. Figure [8](#F8){ref-type="fig"} shows the fraction of observed population variability explained by polymorphisms, non-genetic factors, or both. Of the atorvastatin-lactone hydrolysis variability, 15.0% were explained by *F21F* (rs13226149), *PON3*-*1091A* \> *G* promoter polymorphism and the non-genetic factors sex, CRP, γ-glutamyl transferase, and cancer classification. *PON1* −*108T* \> *C* promoter polymorphism together with non-genetic factors (noted in brackets) determined 13.1% of PON1 mRNA (smoking status, cholestasis) and 35.3% of protein expression (sex, smoking status, CRP, γ-glutamyl transferase). PON3 expression appeared to be affected mainly by non-genetic factors, which explained about 20% of protein variance when smoking status, cancer classification, CRP, bilirubin level, γ-glutamyl transferase were considered, whereas mRNA variation could not be explained reasonably.

![**Percentage of total atorvastatin-lactone hydrolysis, PON1, and PON3 expression variation explained by multivariate linear models containing only non-genetic factors (white), only genetic factors (gray), or both (black)**. The bars indicate the coefficient of determination adjusted for the number of factors in the different models. Linear models were derived by step-wise model selection procedure using Akaike's information criterion.](fphar-02-00041-g008){#F8}

Discussion
==========

In this study we aimed to identify the primary enzyme(s) responsible for atorvastatin-lactone hydrolysis in human liver microsomes and to characterize genetic and non-genetic factors of influence. Our results strongly suggest that both PON1 and PON3 contribute to this reaction and to its interindividual variability, which is an important pathway for atorvastatin biotransformation (Figure [9](#F9){ref-type="fig"}). This conclusion is based on atorvastatin-lactone hydrolysis measurements and population-genetics investigations in a large human liver bank.

![**Proposed pathway for the metabolism of atorvastatin in human liver including Hydroxylation by CYP3A enzymes, Lactonization by UGT1A3, and Hydrolysis of Lactones by PON1 and PON3**.](fphar-02-00041-g009){#F9}

Identification and characterization of PON1 and PON3 in human liver
-------------------------------------------------------------------

We first screened expression profiles of 17 candidate esterase genes for correlation with atorvastatin-lactone hydrolysis activity, revealing several positively and negatively correlated genes. While PON1 and PON3 showed the strongest correlations, butyrylcholinesterase (BCHE) and carboxylesterase 3 (CES3) were less strong but also positively correlated. Although no information on relative expression of these enzymes in liver exists, BCHE is found in plasma (3 mg/l) in an amount comparable to PON3 (1.8 mg/l) and ∼30-fold lower than PON1 (96 mg/l; Nicolet et al., [@B41]; Aragones et al., [@B2]), whereas nothing is known about substrate specificity toward statin-lactones. The negative correlation of PON2 with atorvastatin-lactone hydrolysis seems to point to some degree of co-regulation of the three paraoxonases, as it also correlated negatively with PON1 and PON3 expression data. Although we did not follow up on these other correlated candidate esterase genes, it may be assumed that they contribute to minor extent to the overall hydrolysis reaction in liver.

For PON1 and PON3 we validated these initial correlation results by real-time PCR mRNA quantification based on detailed transcript analyses. These lead to some additional observations on the mRNA level. In contrast to database information, which suggested the existence of up to four and nine transcript variants for PON1 and PON3, respectively, we identified by RT-PCR only a single, so far unknown splice-variant of PON3 with an open reading frame corresponding to 48 additional amino acids. This variant was estimated to be about three-fold less expressed. As it was not detected on western blots, it is most probably either not translated or post-translationally degraded.

At the protein level our work extends previous studies showing PON1 expression in liver (Gonzalvo et al., [@B22]), by the observation of predominantly microsomal localization of human PON3.The similar correlation of PON1 and PON3 (*r*~s~ = 0.60 and 0.62, respectively) to atorvastatin lactonase activity was in agreement with Western blots showing comparable signal intensities for PON1 and PON3 in pooled liver microsomes, although absolute quantification could not be performed due to the lack of standards. The combined protein levels of both paraoxonases accounted for ∼46% of the ∼122-fold variability of atorvastatin-lactone hydrolysis in the liver samples.

Furthermore, by absolute quantification of transcript levels we found PON3 normal transcript to be 4.9-fold higher expressed compared to PON1. This finding contrasts to opposite proportions reported for circulating, HDL-bound PON1 and PON3 in the bloodstream of 96 and 1.8 mg/l, respectively (Aragones et al., [@B2]). A plausible explanation might be strongly favored secretion of PON1 due to its more pronounced glycosylation. This is supported by the fact that N-glycans constitute sorting signals for proteins (André et al., [@B1]).

PON genetics and polymorphisms
------------------------------

Although several SNPs at the PON-locus on chromosome 7 have been previously studied (Wang et al., [@B57]; Carlson et al., [@B11]) this is the first study to look at *PON1* and *PON3* together, which included a thorough genotyping of *PON3* through analysis of 35 SNPs covering the whole gene. Evaluation of the linkage patterns of these SNPs enabled us to define 13 PON1--PON3 haplotypes, which could be grouped into seven major haplotypes based on functionally relevant SNPs. Interestingly these did not include the two amino acid variants L55M and Q192R. Crystal structure analysis revealed that Q192R affects the active histidine dyad of PON1 (Harel et al., [@B27]). However the catalytic consequences are not uniform, as the kinetics of some substrates are accelerated (e.g., paraoxon) whereas others are slowed down (e.g., diazoxon) or not affected (e.g., phenylacetate; Costa and Furlong, [@B12]). According to our studies in liver microsomes, atorvastatin-lactone belongs to the substrates, which are not affected by either of these two variants.

In contrast to the amino acid variants PON1 promoter polymorphisms had a clear effect on expression of PON1 but not PON3. The most influential SNP for atorvastatin-lactone hydrolysis and PON1 expression appeared to be −*108T* \> *C*, which explained 23% of PON1 protein expression in liver, in very good agreement with a previous estimation that this SNP accounts for ∼22--25% of variation in PON1 serum expression in white adults (Costa and Furlong, [@B12]). Functional evidence for −*108T* \> *C* as a causal variant includes approximately two-fold higher activity of the C-allele in a reporter gene assay (Leviev and James, [@B34]), presumably due to disruption of a binding site for the transcription factor Sp1 in the T-allele (Deakin et al., [@B14]), or a binding site for the aryl hydrocarbon receptor, AhR (Gouédard et al., [@B24]).

Furthermore, carriers of the high-expressor C-allele were found to show reduced LDL oxidation following treatment with atorvastatin or simvastatin, presumably due to PON1 induction via promoter binding of SREBP-2 near to the Sp1 site (Deakin et al., [@B14]; Sardo et al., [@B48]). Analysis of statin treatment of our liver donors (*N* = 7, atorvastatin and simvastatin) revealed indeed a trend toward higher PON1 protein levels in treated vs. untreated *PON1-108CC* carriers (*P* = 0.051). On the other hand, protein levels of T-allele carriers on statins were similar or lower than untreated patients with the same allele. Taken together, our findings support --*108T* \> *C* as a causal variant influencing PON1 expression and inducibility, as well as atorvastatin-lactone hydrolysis.

The other two PON1 promoter polymorphisms −*832G* \> *A* and −*1741G* \> *A* were also associated with increased PON1 protein and atorvastatin-lactone hydrolysis. These associations may well be explained by the extensive linkage between the three promoter polymorphisms, although one study reported 1.7-fold higher activity of the −*832A* allele in a reporter gene assay (Leviev and James, [@B34]).

Although the common variations analyzed in this study did not affect PON3 expression, one variant located about 12 kb downstream of the last PON3 exon and about 23 kb upstream of PON1 (var55146, VAF = 5%) was associated with increased protein expression of only PON3, and with marginally increased atorvastatin-lactone hydrolysis, but not with altered mRNA. Whether this association is based on the high linkage to six intronic SNPs (Figure [3](#F3){ref-type="fig"}) or (an) unidentified polymorphism(s) or on a downstream enhancer element of PON3 remains to be clarified. Of interest, most of the identified *PON3* promoter and intronic polymorphisms, as well as *F21F* (rs13226149) and *A99A* (rs1053275), were part of a block of high linkage not affecting PON3 expression, but clearly increasing the expression of PON1.

On the other hand, as shown by multivariate analysis, non-genetic factors clearly influenced PON3 expression more than polymorphisms (Figure [8](#F8){ref-type="fig"}). Observed associations with CRP, γ-glutamyl transferase, bilirubin, cholestasis or treatment with omeprazole or pantoprazole leading to decreased PON3 expression have not been described before. However, decreased expression of PON1 in patients with elevated CRP and γ-glutamyl transferase and down-regulation of PON1 expression in response to inflammatory cytokines has been described before (Van Lenten et al., [@B56]; Han et al., [@B25]; Mackness et al., [@B37]; Araoud et al., [@B3]). PON1 activity has therefore been suggested as a marker for liver impairment (Marsillach et al., [@B39]). The associations with hepatocellular carcinoma (PON1) and cholangiocellular carcinoma (PON3) also seem to be plausible as paraoxonases have a protective effect against oxidative stress, which plays an important role in chronic liver diseases leading to liver cirrhosis and the development of carcinomas (Camps et al., [@B10]).

Materials and Methods {#s1}
=====================

Chemicals
---------

Atorvastatin calcium salt, atorvastatin-d5 sodium salt, atorvastatin-lactone, atorvastatin-d5 lactone, lovastatin, lovastatin-d3, lovastatin hydroxy acid sodium salt, and lovastatin-d3 hydroxy acid sodium salt were purchased from Toronto Research Chemicals Inc. (North York, Canada). All other chemicals were obtained at highest available grade from Sigma-Aldrich (St. Louis, MO, USA).

Liver samples
-------------

Liver tissue and corresponding blood samples were previously collected from patients undergoing liver surgery at the Campus Virchow, Humboldt University, Berlin, Germany. All tissue samples were examined by a pathologist and only histologically non-tumorous tissue was used. Clinical patient documentation for all samples included age, sex, medical diagnosis, presurgical medication, liver functions tests, alcohol and smoking habits, and cancer classification. Patients with hepatitis, cirrhosis or chronic alcohol use were excluded. Finally 150 liver samples, from which high quality RNA and complete documentation could be obtained, were included. The preparation of human liver microsomes had been described before (Lang et al., [@B32]).

Quantification of Atorvastatin-acid and lactone
-----------------------------------------------

Atorvastatin-lactone hydrolysis was determined in human liver microsomes. Incubation time, substrate concentration, and protein content were chosen with care to guarantee measurements within the linear range for each condition. Separate incubation experiments were always carried out together with a denaturated sample of pooled human liver microsomes to guarantee reproducibility and to subtract non-enzymatic conversion. Incubations were performed with 5 μg of protein in 50 mM Tris HCl, pH 7.4 and 1 mM CaCl~2~ in a total volume of 100 μl. The reaction was started by adding 10 μM atorvastatin-lactone (dissolved in acetonitrile). Reactions were stopped after 30 min by adding 100 μl ice-cold 250 mM formic acid/acetonitrile and immediate cooling on ice. After adding 10 μM deuterated atorvastatin and atorvastatin-lactone, the samples were centrifuged and analyzed by LC--MS--MS. HPLC separation was performed at 30°C on a XBridge Shield RP18 column using (A) 1 mM formic acid and (B) acetonitrile at a flow rate of 0.4 ml/min for 20 min. MS--MS analysis was performed on an Esquire HCT ultra ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany). Lovastatin hydrolysis was determined under similar conditions using 100 μg pooled HLMs and 50 μM lovastatin for the performed preliminary experiment. As internal standard, deuterated lovastatin-acid and lovastatin-lactone were used. Precursor and product ions (m/z) were ATV (559 and 440.2; 466.2), \[^2^H~5~\]ATV (564 and 445.2; 471.2), ATV-L (541.2 and 448.2), \[^2^H~5~\]ATV-L (546.2 and 453.2), LOV-A (422 and 445.1), \[^2^H~3~\]LOV-A (425 and 448.1), LOV-L (404 and 427.1), \[^2^H~3~\]LOV-L (407 and 430.1). Sodium adducts were used in the quantification of lovastatin and its metabolites. Possible quantification ranged from 0.5 to 500 pmol per sample. Gradient program and MS--MS conditions are available on request.

Immunoblotting
--------------

Relative protein quantification of microsomal and cytosolic samples was performed by western blot analysis using monoclonal antibodies against PON1 (sc-59646, Santa Cruz; 1:1000) and PON3 (ab71994, Abcam; 1:2000). Electrophoretic separation of samples in Laemmli-buffer was done on a 10% SDS-polyacrylamide gel. Proteins were transferred by semidry-blotting onto a nitrocellulose membrane. Membranes were blocked for 1 h at room temperature. Primary antibodies were diluted in 1% skim milk-TBST and blots were incubated for 1 h at room temperature or over night at 8°C in this solution. Membranes were washed and incubated (under protection from light) for 30 min at room temperature with the corresponding secondary antibody (1:10000). Finally, membranes were washed again and the ODYSSEY infrared imaging system (LI-COR) was used for detection. Relative quantification was performed based on standard curves of pooled human liver microsomes recorded on each blot. Results were expressed in relation to pooled human liver microsomes. For molecular weight estimation, high range rainbow marker (14.3--220 kDa; Amersham Biosciences) was used. Lysate of primary human hepatocytes was analyzed for PON3 expression applying similar conditions. Immunoblotting of lysate was performed using a LI-COR MPX (Multiplex) Blotter.

Deglycosylation of microsomal samples was performed according to the manufacturer's protocol by incubation with endoglycosidase PNGase F (New England Biolabs, Ipswich, MA, USA) for 1 h at 37°C after denaturation at 100°C for 10 min. For quantification of microsomal expression, the combined intensity of stained bands in untreated (glycosylated) samples was used.

Quantification of mRNA expression
---------------------------------

Total RNA was prepared from liver tissue by Trizol (Invitrogen, Paisley, FL, USA) extraction and using the RNeasy Mini Kit with on-column DNase treatment (Qiagen, Hilden, Germany) as described previously (Gomes et al., [@B21]). Only high quality RNA preparations according to Agilent Bioanalyzer (Nano-Lab Chip Kit, Agilent Technologies, Waldbronn, Germany) RIN assignment (\>7) were used in this study. Two hundred nanograms of total RNA was amplified and labeled using the Illumina TotalPrep RNA Amplification kit (Ambion Applied Biosystems, Darmstadt, Germany). cRNA quality was assessed by capillary electrophoresis on Agilent 2100 Bioanalyzer (Agilent Technologies). Expression levels of mRNA transcripts were assessed by the Human-6 v3 Expression BeadChips (Illumina, Eindhoven, Netherlands). Hybridization was carried out according to the manufacturer's instructions. Quantil normalized expression data of the 15 candidate esterases was used in the analysis.

For PCR based quantification, synthesis of cDNA was performed with 1 μg RNA using the TaqMan Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany) according to the supplier's instructions. Quantification of PON1, PON3 *wildtype*, and PON3 *splice-variant* mRNA was performed by specific TaqMan real-time reverse-transcription PCR on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using exon--exon boundary spanning primers (Table [A2](#TA2){ref-type="table"} in Appendix; 400 nM each) and FAM-labeled MGB probes (Table [A2](#TA2){ref-type="table"} in Appendix; 200 nM). Specificity for PON1 was confirmed using DNA plasmids constructed from PON1 and PON3 *wildtype* complete cDNA (see Table [A3](#TA3){ref-type="table"} in Appendix for full-length amplification primers), which were used as a linearized PON1 Taqman standard (10 fg/μl--1 pg/μl) and PON3 *wildtype* negative control (1--100 pg/μl). Position of primers and probes were shown according to cDNA NM_000446.5 (PON1) and NM_000940.2 (PON3). Specificity for PON3 *wildtype* and *splice-variant* were confirmed using DNA plasmids constructed from PON3 *wildtype* and *splice-variant* complete cDNA, which were used as linearized Taqman standard (10 fg/μl--1 pg/μl) and as negative control vice versa (1--100 pg/μl). PCR was performed using 2× universal PCR Master Mix (Applied Biosystems) in a final volume of 12.5 μl and the following cycling conditions: 50°C for 2 min; 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Results were normalized to RPLP0 (60S large ribosomal protein P0) and expressed in relation to the lowest value, which was set at 1.0. Four extreme values of PON1 mRNA (between rel. units 26 and 120) were excluded from subsequent analyses.

Genotyping
----------

### Selection of polymorphisms for genotyping

Polymorphisms for *PON*-locus genotyping were derived from dbSNP database (six coding, three promoter, four intronic, one 3′UTR polymorphisms) and seattle SNP database (from this database six tagging polymorphisms with a VAF \> 0.05 covered 72 polymorphisms; one tagging polymorphism with VAF \> 0.02 covered 77 polymorphisms). Additional polymorphisms were found in literature (two promoter SNPs from Marsillach et al., [@B39]; 12 intronic polymorphisms from Wang et al., [@B57]; Campo et al., [@B9]; Ranade et al., [@B44]; Carlson et al., [@B11]; Erlich et al., [@B18]; Saeed et al., [@B46]; Sanghera et al., [@B47]). Two *PON1* coding polymorphisms (L55M, Q192R) were derived from Dahabreh et al. ([@B13]). Genomic positions of polymorphisms refer to reference sequence PON3 NG_008726.1 (modified by adding *PON1* NG_008779 and the intergenic region in between). SNP numbering differences occurred in various studies for PON1 promoter SNPs (−107 = −108; −824 = −832 according to Draganov and La Du, [@B16]). Database VAFs were extracted from Caucasian samples from one of these selections: dbSNP, build 132: (HapMap-CEU, pilot.1.CEU, PGA-EUROPEAN-PANEL); Seattle SNP (23 CEPH samples). Literature data was derived from these populations: 1143 southern Italians (Campo et al., [@B9]); 2634 Caucasians (Ranade et al., [@B44]); 949 Chinese (Wang et al., [@B57]). Polymorphisms were assigned by dbSNP rs number, Seattle SNP var number, amino acid change or naming within literature.

### MALDI-TOF MS assay

Thirty-seven polymorphisms were genotyped by two MALDI-TOF MS assays. Primers (Table [A4](#TA4){ref-type="table"} in Appendix) were designed to specifically amplify regions around polymorphisms and carried a tag sequence (ACGTTGGATG) to avoid interactions with the MALDI-TOF MS analysis. Correct amplification was confirmed by sequencing. MassArray Assay Design (v3.0.0) was used for the design of MALDI-TOF MS extension primers. Two different assays were developed to include all 37 DNA variations analyzed (Table [A5](#TA5){ref-type="table"} in Appendix). Each assay consisted of preamplification by PCR, shrimp alkaline phosphatase (SAP) treatment, iPLEX primer extension, and a clean resin step. Samples were transferred to a 384 SpectroCHIP® Array (Sequenom) and analyzed in a MassArrayTM Compact mass spectrometer (Sequenom). Automated spectra acquisition was performed using Spectroacquire and data analysis was performed with MassArray Typer software v3.4. Further details are available on request.

Data for rs757158 (SNP 37) and rs854571 (SNP 38) were obtained from HumanHap300v1.1 chip analysis (Microarray Facility Tübingen Services, Tübingen, Germany). rs705379 (SNP 36) was genotyped using a predesigned TaqMan allelic discrimination assay (C_11708905_10; Applied Biosystems, Darmstadt, Germany) using TaqMan 7900HT (Applied Biosystems, Darmstadt, Germany).

### Statistical analysis and computational genetic analysis

GraphPad Prism v4.00 (GraphPad Software Inc., San Diego, CA, USA) was applied for Spearman correlation analysis of (a) enzymatic atorvastatin-lactone hydrolysis activity with mRNA expression of selected candidate genes and (b) PON1 and PON3 mRNA and protein expression. Effects of non-genetic factors on enzymatic atorvastatin-lactone hydrolysis activity and PON1/3 mRNA/protein expression were tested by Wilcoxon--Mann--Whitney-tests. Fold-changes are representing observed differences between median values of corresponding phenotypes.

Observed and expected allele and genotype frequencies within populations were tested for deviation from Hardy--Weinberg equilibrium using the online DeFinetti program (Hardy-Weinberg Equilibrium, [@B26]). No deviation from Hardy--Weinberg equilibrium was detected for any of the SNPs analyzed. Linkage disequilibrium (LD) plots were created by Haploview 4.2 (Barrett et al., [@B6]). Haplotypes for the *PON*-locus were generated with statistical software R v2.11.1 (The R Project for Statistical Computing, [@B54]) using the library haplo.stats v1.4.4. Exclusion criterion for polymorphisms was a VAF \< 2%. In case of 100% linked polymorphisms, only one representative was chosen and, if missing data occurred, completed by the 100% correlated polymorphisms. An iterative two-step expectation-maximization algorithm was applied to predict haplotype assignment of individuals based on activity data and polymorphisms (log-additive genetic model). Rare haplotypes were defined by a haplotype frequency \<2% and were not included in further analyses. Resulting 13 haplotypes were manually combined to seven major types according to occurrence of *PON1* promoter and *PON3* *F21F* and four promoter polymorphism (Table [4](#T4){ref-type="table"}). Wilcoxon--Mann--Whitney-tests were used to compare (a) carriers of identified haplotypes vs. carriers of reference haplotypes (*^\*^1* or *^\*^1*/*^\*^1*) and (b) for each of the selected *PON1*/*3* polymorphisms, heterozygote and homozygote carriers of variant allele vs. homozygote carriers of reference allele.

Moreover, multivariate linear models and step-wise model selection based on Akaike's information criterion were applied to determine the contribution of polymorphisms and non-genetic factors to atorvastatin-lactone hydrolysis and PON1 and PON3 expression variability. In this analysis, atorvastatin-lactone hydrolysis and PON1 and PON3 expression were first log-transformed in order to satisfy Gaussian distribution assumption. Normality of log-transformed values was verified by normal quantile--quantile plots. Moreover, for each polymorphism, the genetic model (dominant, recessive, or log-additive) with the most significant effect on the corresponding phenotype in the univariate analyses was chosen. Relevant polymorphisms in this analysis were: *PON3* −*4984* (var1496), −*1091* (rs11767787), *F21F* (rs13226149), *PON1* −*1741* (rs757158), and −*108* (rs705379). The coefficients of determination adjusted for the number of factors in the considered models were then used to specify the fraction of phenotype variability explained by (a) only polymorphisms, (b) only non-genetic factors, and (c) both, polymorphisms and non-genetic factors.

All tests were two-sided and statistical significance was defined as *P* \< 0.05.

Conclusion
==========

PON1 and PON3 were identified as the major enzymes for hydrolysis of atorvastatin-lactone in human liver. Although this study focused on the transformation from atorvastatin-lactone to atorvastatin-acid, it is very likely that these two enzymes also convert the corresponding hydroxyl-metabolites. Based on thorough polymorphism analysis, the two common amino acid variants L55M and Q192R did not seem to be of functional importance, while several rare protein variants were not present in our collection. Our data show that PON1 expression is governed mainly by the linked promoter polymorphisms −*108T* \> *C*, −*832G* \> *A*, and −*1741G* \> *A*, the former of which likely represents the causal variant. Accordingly, haplotypes defined on the basis of this variant show significant changes in expression and atorvastatin-lactone hydrolysis. Our extensive analysis of PON3 polymorphisms failed to identify functional polymorphisms affecting PON3, which appears to be more subject to control by non-genetic factors. As atorvastatin-lactone has been associated with toxicity, these data may help to improve concepts for safer use of statins.
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###### 

**Characteristics and variant allele frequencies (VAF) of polymorphisms determined in 150 Caucasian samples**.

  SNP   Gene     SNP ID dbSNP or Seattle SNP   Genomic position   Base change   Residue change   Region       VAF     
  ----- -------- ----------------------------- ------------------ ------------- ---------------- ------------ ------- -------
  1     *PON3*   var1496                       42                 A/G                            Promoter     0.295   0.200
  2     *PON3*   var2115                       661                A/T                            Promoter     0.087   0.200
  3     *PON3*   var2375                       921                G/A                            Promoter     0.288   0.200
  4     *PON3*   rs11767787                    3935               A/G                            Promoter     0.309   0.241
  5     *PON3*   rs17885453                    4232               C/T                            Promoter     0.014   0.023
  6     *PON3*   rs17882539                    4280               C/T                            Promoter     0.295   0.181
  7     *PON3*   rs2072200                     4528               C/G                            Promoter     0.198   0.272
  8     *PON3*   rs13226149                    5088               C/T           F21F             Exonic       0.309   0.250
  9     *PON3*   var9827                       8372               G/A                            Intronic     0.183   0.300
  10    *PON3*   rs10487132                    10383              T/C                            Intronic     0.360   0.383
  11    *PON3*   var12788                      11333              C/T                            Intronic     0.486   0.430
  12    *PON3*   rs1003504                     11895              A/G                            Intronic     0.018   0.022
  13    *PON3*   rs978903                      26521              T/C                            Intronic     0.497   0.458
  14    *PON3*   Campo219                      29055              C/G           G51G             Intronic     0.004   0.007
  15    *PON3*   rs1053275                     29133              G/A           A99A             Exonic       0.493   0.466
  16    *PON3*   rs2375003                     29155              G/A           D107N            Exonic       0       0
  17    *PON3*   rs2375002                     29330              T/A                            Intronic     0.09    0.043
  18    *PON3*   rs468                         32735              T/C                            Intronic     0.096   0.025
  19    *PON3*   Wang.133                      33772              G/T                            Intronic     0.004   0.227
  20    *PON3*   rs3757708                     33775              A/C                            Intronic     0.489   0.483
  21    *PON3*   rs17879114                    33898              G/A           V126V            Exonic       0       0
  22    *PON3*   rs17878827                    33956              G/A           E146K            Exonic       0       0
  23    *PON3*   var37120                      35664              G/A                            Intronic     0.036   0.110
  24    *PON3*   rs9640632                     36134              A/G                            Intronic     0.482   0.483
  25    *PON3*   rs17883013                    37354              C/A           A179D            Exonic       0       0
  26    *PON3*   rs17880470                    37427              T/C           Y203Y            Exonic       0.014   0.022
  27    *PON3*   Ranade                        38537              A/G           Y233C            Exonic       0       0
  28    *PON3*   var40512                      39056              A/G                            Intronic     0.183   0.300
  29    *PON3*   rs2057682                     39924              C/G                            Intronic     0.142   0.076
  30    *PON3*   rs7778771                     40352              C/T                            Intronic     0.014   0.025
  31    *PON3*   Campo931                      41269              T/A           S311T            Exonic       0       0.002
  32    *PON3*   Campo971                      41309              G/A           G324D            Exonic       0       0.006
  33    *PON3*   rs17885558                    41438              C/T                            3(UTR        0.014   0.025
  34             var45486                      \(44028\)          G/T                            Intergenic   0.014   0.050
  35             var55146                      \(53688\)          G/A                            Intergenic   0.050   0.100
  36    *PON1*   rs757158                      \(75164\)          G/A                            Promoter     0.486   0.408
  37    *PON1*   rs854571                      \(76073\)          A/G                            Promoter     0.285   0.267
  38    *PON1*   rs705379                      \(76797\)          T/C                            Promoter     0.460   0.389
  39    *PON1*   rs854560                      \(84608\)          T/A           L55M             Exonic       0.335   0.397
  40    *PON1*   rs662                         \(93246\)          A/G           Q192R            Exonic       0.352   0.358

###### 

**Amplification primers used for quantitative PCR**.

  Name                 cDNA position          Primer sequence (5′ → 3′)       Amplification product (bp)   Purpose
  -------------------- ---------------------- ------------------------------- ---------------------------- ------------
  TQ_PON3_for          181--209               TGAAGATATTGATATACTTCCTAGTGGGC                                For primer
  TQ_PON3_WT_rev       297--316               TGCCCTTGGGTTTTGTTCAT            Wt: 136, var: 132            Rev primer
  TQ_PON3_VAR_rev      67--86 (Exon splVar)   TATTTGCCGTTCTGCAGCCT                                         Rev primer
  TQ_PON3_WT           218--234               6FAM-ATCTCCAGTGGATTAAA-MGB                                   Probe
  TQ_PON3_VAR          218--8 (Exon splVar)   6FAM-ATCTCCAGTCTGCAGGT-MGB                                   Probe
  PON1_Hs00166557_m1   994--1018              TCCTGCATCAGAGGTGCTTCGAATC       122                          Mix

###### 

**Amplification primers used for plasmid generation**.

  Name               cDNA Position   Primer sequence (5′ → 3′)      Amplification product (bp)   Purpose
  ------------------ --------------- ------------------------------ ---------------------------- ------------
  PON3_komplett_f    1--16           AGATCTAGTCGCCGCTGGGCAC         1203                         For primer
  PON3_komplett_r    1170--1193      AAGCTTTTGGTGTTTGCTATTTACTTAC                                Rev primer
  PON1_kompl_neu_f   95--115         ACCATGGCGAAGCTGATTGCG          1239                         For primer
  PON1_kompl_neu_r   1306--1327      GAATTCTACACATCATATCACTCCCAGT                                Rev primer

###### 

**Amplification primers used in MALDI-TOF MS genotyping**.

  Name          Genomic position   Primer sequence (5′ → 3′)         Amplification product (bp)   SNP ID
  ------------- ------------------ --------------------------------- ---------------------------- ----------------------
  PON3_1f       3882--3982         ACGTTGGATGTAAGCAATCTGTGCTGCAGG    111                          rs11767787
  PON3_1r                          ACGTTGGATGGCTGACACCTATGTTAACGC                                 
  PON3_2f       4148--4256         ACGTTGGATGTCGGTGGAACCTAACAGAAC    119                          rs17885453
  PON3_2r                          ACGTTGGATGACTGAAGATGCGGGAAGA                                   
  PON3_3f       4256--4318         ACGTTGGATGTTCCTCCCCCTCCAACCT      73                           rs17882539
  PON3_3r                          ACGTTGGATGTCCTGCCAGGCAAGAAATG                                  
  PON3_6f       4496--4580         ACGTTGGATGAAGGCAATCGAAGCGAAGAG    95                           rs2072200
  PON3_6r                          ACGTTGGATGAGGTAAGGCACGAAGGTCAG                                 
  PON3_7f       4944--5039         ACGTTGGATGATCCGTACGCGAGGCAGGAA    106                          rs17886586
  PON3_7r                          ACGTTGGATGACGAGCTTCCCCATGGTCTC                                 
  PON3_8f       5058--5156         ACGTTGGATGGGTCGGCCTGTCCTTAGTC     109                          rs13226149
  PON3_8r                          ACGTTGGATGCTCACTTGGAAGAGGAGAG                                  
  PON3_10f      10322--10421       ACGTTGGATGTTCCCACACACTTATTAGCC    110                          rs10487132
  PON3_10r                         ACGTTGGATGACAGGCTAAGAAGCAGTAGG                                 
  PON3_11_12f   29232--29107       ACGTTGGATGAATGAACAAAACCCAAGGGC    136                          rs1053275, rs2375003
  PON3_11_12r                      ACGTTGGATGCCCCTTATCCCTAAACATAC                                 
  PON3_13f      32673--32769       ACGTTGGATGGTGAGAGTACTTTTCTTCTCC   107                          rs468
  PON3_13r                         ACGTTGGATGGTCATCTCCCTTAATTATG                                  
  PON3_14f      33844--33927       ACGTTGGATGGATAGGGGTAACTTTCTTGG    94                           rs17879114
  PON3_14r                         ACGTTGGATGATGTGGGGATGATTCACAAC                                 
  PON3_15f      33928--34038       ACGTTGGATGCCGCACAATACTTTCATTCC    121                          rs17878827
  PON3_15r                         ACGTTGGATGGAAGTCCACTGTGGAGATAT                                 
  PON3_16f      36189--36095       ACGTTGGATGTCAGGCTCCTCTTTAGATCC    105                          rs9640632
  PON3_16r                         ACGTTGGATGCTCTGGGAAGTACATCAGAC                                 
  PON3_17f      37280--37383       ACGTTGGATGGGGAGTTGGTAAAATAGTGG    114                          rs17883013
  PON3_17r                         ACGTTGGATGTGGGTCTCTTTTTCCACCTC                                 
  PON3_18f      37398--37496       ACGTTGGATGGAGATGATCTTGGATCTTCG    109                          rs17880470
  PON3_18r                         ACGTTGGATGTGTGATCCCATTGGCACTAC                                 
  PON3_19f      39847--39951       ACGTTGGATGTTGTACTTTCTCAATGAGGC    115                          rs2057682
  PON3_19r                         ACGTTGGATGAAGGCTCAGCAGAGTAAAGG                                 
  PON3_20f      40313--40426       ACGTTGGATGGATACATAGGATTATTGGAG    124                          rs7778771
  PON3_20r                         ACGTTGGATGAAAGGGTGTCAGTAATTGTG                                 
  PON3_21f      41395--41513       ACGTTGGATGACTCACTGGTTGGTGTTTGC    129                          rs17885558
  PON3_21r                         ACGTTGGATGGAGCTCTAGACTCTAGATAG                                 
  PON3_W2_1f    1--96              ACGTTGGATGGCAGAAGACATTACTCAGAC    106                          var1496
  PON3_W2_1r                       ACGTTGGATGCCTAATCATCATTTTCAGGC                                 
  PON3_W2_3f    594--688           ACGTTGGATGCAGATTCTCCAAGCCTAGAC    105                          var2115
  PON3_W2_3r                       ACGTTGGATGATGTTTAGGTGGAGGGACTG                                 
  PON3_W2_4f    877--965           ACGTTGGATGTTGAATCTGGAGAGGAAGGC    99                           var2375
  PON3_W2_4r                       ACGTTGGATGTGTTACTTCCAGTGGCTTCC                                 
  PON3_W2_9f    8318--8418         ACGTTGGATGTTGTGCTAGCAGCTGGAAAG    111                          var9827
  PON3_W2_9r                       ACGTTGGATGTCCCTTCTCCAACAGAATCC                                 
  PON3_W2_13f   11306--11405       ACGTTGGATGTGGGCATTCCTGTGGTGTTC    110                          var12788
  PON3_W2_13r                      ACGTTGGATGTGGATCCCTATGCTCTCATC                                 
  PON3_W2_14f   11833--11960       ACGTTGGATGGTGTATTTATGAGATGTTG     138                          rs1003504
  PON3_W2_14r                      ACGTTGGATGTTCCAGCAATCAGAATTCAC                                 
  PON3_W2_15f   26476--26564       ACGTTGGATGGTATAGAGTGAGAAGGGAGG    99                           rs978903
  PON3_W2_15r                      ACGTTGGATGCCCAGATAGAAATCCTGCTC                                 
  PON3_W2_16f   29001--29088       ACGTTGGATGTGTATATGTGTGCACACTTG    98                           Campo219
  PON3_W2_16r                      ACGTTGGATGTTTTCCTGGTTCATCTGGCG                                 
  PON3_W2_17f   29283--29404       ACGTTGGATGCCACATAGGGCCAAAAATAC    132                          rs2375002
  PON3_W2_17r                      ACGTTGGATGAACAGGAAGAGAGAAGATGC                                 
  PON3_W2_18f   33734--33863       ACGTTGGATGTGGCATTTGTCTGACTTACC    140                          Wang133
  PON3_W2_18r                      ACGTTGGATGCCAAGAAAGTTACCCCTATC                                 
  PON3_W2_20f   35612--35710       ACGTTGGATGGAAGGATCCTTCCCTAGAAC    109                          var37120
  PON3_W2_20r                      ACGTTGGATGCCAGAAATGTATTGCCTCGC                                 
  PON3_W2_22f   38481--38564       ACGTTGGATGTTAGCTGCTACATCAGCTAC    94                           Y233C
  PON3_W2_22r                      ACGTTGGATGGAGTGTTGTCTCTCATTACC                                 
  PON3_W2_23f   38982--39093       ACGTTGGATGTTCTTCCAAGTCACCCCAAC    123                          var40512
  PON3_W2_23r                      ACGTTGGATGAACTATAACCCTGAGGACCC                                 
  PON3_W2_25f   41234--41349       ACGTTGGATGTTTCTCGACAGGTACTTCGC    126                          S311T
  PON3_W2_25r                      ACGTTGGATGATGGTACACAGAAGCCACAG                                 
  PON3_W2_26f   41234--41349       ACGTTGGATGTTTCTCGACAGGTACTTCGC    126                          G324D
  PON3_W2_26r                      ACGTTGGATGATGGTACACAGAAGCCACAG                                 
  PON3_W2_27f   (43979--44080)     ACGTTGGATGTTGGATTCCTCCTGGAGTAG    112                          var45486
  PON3_W2_27r                      ACGTTGGATGTTGAAGGGAGATGACAAGGC                                 
  PON3_W2_28f   (53627--53721)     ACGTTGGATGGTGATATTGAAGTCCTCCTC    105                          var55146
  PON3_W2_28r                      ACGTTGGATGTCAAAGAACCTAGACCCAGC                                 
  PON3_W2_31f   (84581--84698)     ACGTTGGATGTTTCTGGCAGAAACTGGCTC    128                          rs854560
  PON3_W2_31r                      ACGTTGGATGGCCAGTCCTAGAAAACGTTC                                 
  PON3_W2_32f   (93191--93291)     ACGTTGGATGGGACCTGAGCACTTTTATGG    111                          rs662
  PON3_W2_32r                      ACGTTGGATGTAGACAACATACGACCACGC                                 

###### 

**Extension primers used in MALDI-TOF MS genotyping**.

  No.   Name             Genomic position   Assay   Primer sequence (5′ → 3′)      Mass of ampl. prod. (Da)   SNP ID
  ----- ---------------- ------------------ ------- ------------------------------ -------------------------- ------------
  1     PON3_W2_1e       42                 2       ggCCTTTCTTAAGAAAGGGCTAAT       7391.8                     var1496
  2     PON3_W2_3e       661                2       CACCACCCCTTTGCTCATATCCAA       7152.7                     var2115
  3     PON3_W2_4e       921                2       GTAGGCCAAGTTAAGAAAC            5869.9                     var2375
  4     PON3_W2_5e       3935               2       AATTATCAACACAATCTCTGGAG        7015.6                     rs11767787
  5     PON3_2e          4232               1       TGCTACTTTGCCCGAACT             5425.5                     rs17885453
  6     PON3_3e          4280               1       CCTCCAACCTGGTGTT               4808.1                     rs17882539
  7     PON3_6e          4528               1       ATCTTCTCCAGGATTTGGGGCAC        7030.6                     rs2072200
  8     PON3_8e          5088               1       agTAGTCGGGGAGATGTT             5634.7                     rs13226149
  9     PON3_W2_9e       8372               2       ACGCCTTTCCTGAATT               4807.1                     var9827
  10    PON3_10e         10383              1       cGCCTATGCACAACTATCATTA         6638.3                     rs10487132
  11    PON3_W2_13e      11333              2       GGCTTTTTTAGTTGACTGGTTTACCC     7949.2                     var12788
  12    PON3_W2_14e      11895              2       ggATTTGTTAAATCAATTGCATTTTG     8005.2                     rs1003504
  13    PON3_W2_15e      26521              2       TCGATAAAAACAGAAGGAGG           6232.1                     rs978903
  14    PON3_W2_16e      29055              2       AAAAGGGATTAAAATATCCAGG         6824.5                     Campo219
  15    PON3_11e         29133              1       ggAACCCAAGGGCACAAGC            5840.8                     rs1053275
  16    PON3_12e         29155              1       CCATGTGGATTAAATAATTCTTTGT      7661                       rs2375003
  17    PON3_W2_17e      29330              2       cCAAGGTTTTATACCTATTTATCATTT    8189.4                     rs2375002
  18    PON3_13e         32735              1       gTTCTCCATCTCCTCATTCC           5929.9                     rs468
  19    PON3_W2_18\#1e   33772              2       ACCTATCATGTAGACTGTGAG          6445.2                     Wang133
  20    PON3_W2_18\#2e   33797              2       TTTCTTCTTACATCTTGCATTT         6607.3                     rs3757708
  21    PON3_14e         33898              1       gTTCCATGTAGACAATACTGT          6420.2                     rs17879114
  22    PON3_15e         33956              1       AGAGAACGTTGTTGTTCCT            5833.8                     rs17878827
  23    PON3_W2_20e      35664              2       CATGGCCCTACCAATAACAC           6014.9                     var37120
  24    PON3_16e         36134              1       GTTCCAGCTGCTGCTA               4848.2                     Campo219
  25    PON3_17e         37354              1       AATAGTGGTCTCTGGTG              5256.4                     rs2375002
  26    PON3_18e         37427              1       cGATCTTCGCTGGACTTA             5465.6                     rs17880470
  27    PON3_W2_22e      38537              2       GCTGCTACATCAGCTACATAGACA       7305.8                     Y233C
  28    PON3_W2_23e      39056              2       ACCCCAACAAATTTGTTC             5402.5                     var40512
  29    PON3_19e         39924              1       TTCTCAATGAGGCCTACTCT           6042.9                     rs2057682
  30    PON3_20e         40352              1       GGAGAATTGTTTAGGATCTTTTT        7114.6                     rs7778771
  31    PON3_W2_25e      41269              2       CGCATCCAGAATGTTTTG             5489.6                     S311T
  32    PON3_W2_26e      41309              2       ttCACCGTGTATGCCAACAATG         6694.4                     G324D
  33    PON3_21e         41438              1       CAATTATCAGTTTACTTTTACAAAATAT   8519.6                     rs17885558
  34    PON3_W2_27e      44028              2       CCATTCTTTCCAAAGGATAG           6076                       var45486
  35    PON3_W2_28e      53688              2       gACCTTGAGGCAATGTG              5250.4                     var55146
  39    PON3_W2_31e      84608              2       AACTGGCTCTGAAGAC               4890.2                     rs854560
  40    PON3_W2_32e      93246              2       gTTCTTGACCCCTACTTAC            5689.7                     rs662
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